{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:53:54Z","timestamp":1792083234709,"version":"4.4.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2019_EKMS.49"],"award-info":[{"award-number":["2019_EKMS.49"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1700\/21"],"award-info":[{"award-number":["1700\/21"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["404521405"],"award-info":[{"award-number":["404521405"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["PL315\/10-1"],"award-info":[{"award-number":["PL315\/10-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1389"],"award-info":[{"award-number":["SFB 1389"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP 2395"],"award-info":[{"award-number":["SPP 2395"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022805","name":"Dieter Morszeck Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005385","name":"Council for Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022716","name":"Swiss Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020027","name":"Dr. Rolf M. Schwiete Stiftung","doi-asserted-by":"publisher","award":["PL-315\/9-1"],"award-info":[{"award-number":["PL-315\/9-1"]}],"id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020027","name":"Dr. Rolf M. Schwiete Stiftung","doi-asserted-by":"publisher","award":["39404578"],"award-info":[{"award-number":["39404578"]}],"id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020027","name":"Dr. Rolf M. Schwiete Stiftung","doi-asserted-by":"publisher","award":["CRC1366"],"award-info":[{"award-number":["CRC1366"]}],"id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020027","name":"Dr. Rolf M. Schwiete Stiftung","doi-asserted-by":"publisher","award":["RTG2727 - 445549683"],"award-info":[{"award-number":["RTG2727 - 445549683"]}],"id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020027","name":"Dr. Rolf M. Schwiete Stiftung","doi-asserted-by":"publisher","award":["2021-009"],"award-info":[{"award-number":["2021-009"]}],"id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","award":["01028753"],"award-info":[{"award-number":["01028753"]}],"id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ccell.2022.12.007","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T10:33:56Z","timestamp":1673519636000},"page":"235-251.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":120,"title":["MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors"],"prefix":"10.1016","volume":"41","author":[{"given":"Michael","family":"Kilian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Sheinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Leng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Kaminitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khwab","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chan","family":"Chih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Cichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"J\u00e4hne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Ratliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Etminan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"von Deimling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Madi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-887X","authenticated-orcid":false,"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2022.12.007_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.12.007_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T cell dysfunction in cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T\u00a0cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2022.12.007_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T\u00a0cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib6","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.cell.2016.08.052","article-title":"A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T\u00a0cells","volume":"166","author":"Singer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T\u00a0cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T\u00a0cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T\u00a0cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T\u00a0cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib11","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T\u00a0cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.12.007_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","article-title":"Transcriptomic profiles of neoantigen-reactive T\u00a0cells in human gastrointestinal cancers","volume":"40","author":"Zheng","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ccell.2022.12.007_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.12.007_bib15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ccell.2022.12.007_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T\u00a0cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib17","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib20","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2022.12.007_bib21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T\u00a0cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.007_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.007_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","article-title":"Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma","volume":"25","author":"Zhao","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.007_bib25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T\u00a0cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.007_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s43018-021-00201-z","article-title":"Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas","volume":"2","author":"Friedrich","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ccell.2022.12.007_bib27","doi-asserted-by":"crossref","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","article-title":"Immunosuppressive mechanisms in glioblastoma","volume":"17","author":"Nduom","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ccell.2022.12.007_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI121266","article-title":"Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target","volume":"129","author":"Wei","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2022.12.007_bib29","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41467-020-14642-0","article-title":"Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas","volume":"11","author":"Aslan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.12.007_bib30","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nri.2015.10","article-title":"The multifaceted role of CD4+ T\u00a0cells in CD8+ T\u00a0cell memory","volume":"16","author":"Laidlaw","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T\u00a0cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib34","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ccell.2022.12.007_bib35","first-page":"noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial","author":"Omuro","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ccell.2022.12.007_bib36","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T\u00a0cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.12.007_bib37","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.celrep.2017.10.030","article-title":"Single-cell RNA-seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma","volume":"21","author":"Darmanis","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ccell.2022.12.007_bib38","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/nn.3531","article-title":"A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation","volume":"16","author":"Goldmann","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ccell.2022.12.007_bib39","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","author":"Reardon","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2022.12.007_bib40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib41","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-020-2611-3","article-title":"cDC1 prime and are licensed by CD4+ T\u00a0cells to induce anti-tumour immunity","volume":"584","author":"Ferris","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib42","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.12.007_bib43","article-title":"Identification of factors mediating the signaling convergence of multiple receptors following cell-cell interaction","author":"Sheinin","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2022.12.007_bib44","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1073\/pnas.1913940117","article-title":"CD29 identifies IFN-\u03b3-producing human CD8+ T\u00a0cells with an increased cytotoxic potential","volume":"117","author":"Nicolet","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2022.12.007_bib45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/intimm\/7.5.835","article-title":"Identification and functional characterization of mouse CD29 with a mAb","volume":"7","author":"Noto","year":"1995","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12032-015-0595-x","article-title":"The role of CD29-ILK-Akt signaling-mediated epithelial\u2013mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells","volume":"32","author":"Jiang","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ccell.2022.12.007_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cellsig.2009.10.003","article-title":"Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase","volume":"22","author":"Saunders","year":"2010","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ccell.2022.12.007_bib48","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T\u00a0cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib49","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T\u00a0cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib50","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","article-title":"Inhibitory CD161 receptor identified in glioma-infiltrating T\u00a0cells by single-cell analysis","volume":"184","author":"Mathewson","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib52","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint blockade immunotherapy induces dynamic changes in PD-1\u00a0\u2212 CD8\u00a0+ tumor-infiltrating T\u00a0cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.12.007_bib54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1\u00a0+ PD-1\u00a0+ CD8\u00a0+ T\u00a0cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.12.007_bib55","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T\u00a0cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib56","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ccell.2017.09.014","article-title":"H3.3 K27M cooperates with Trp53 loss and PDGFRA gain in mouse embryonic neural progenitor cells to induce invasive high-grade gliomas","volume":"32","author":"Pathania","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ccell.2022.12.007_bib58","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib59","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2119\/molmed.2011.00217","article-title":"Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling","volume":"18","author":"Coniglio","year":"2012","journal-title":"Mol. Med."},{"key":"10.1016\/j.ccell.2022.12.007_bib60","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2022.12.007_bib61","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.12.007_bib62","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/brain\/aww355","article-title":"Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis","volume":"140","author":"Poon","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ccell.2022.12.007_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.12.007_bib64","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","article-title":"Macrophage regulation of tumor responses to anticancer therapies","volume":"23","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T\u00a0cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib66","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","article-title":"CD4+ T\u00a0cell help confers a cytotoxic T\u00a0cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness","volume":"47","author":"Ahrends","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.12.007_bib67","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1038\/s41467-019-13438-1","article-title":"CD4+ T\u00a0cell help creates memory CD8+ T\u00a0cells with innate and help-independent recall capacities","volume":"10","author":"Ahrends","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2022.12.007_bib68","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.immuni.2019.10.009","article-title":"CD4+ T\u00a0cell help is required for the formation of a cytolytic CD8+ T\u00a0cell subset that protects against chronic infection and cancer","volume":"51","author":"Zander","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ccell.2022.12.007_bib69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","article-title":"Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T\u00a0cell immunity","volume":"177","author":"Binnewies","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib70","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/2326-6066.CIR-16-0156","article-title":"Endogenous neoantigen-specific CD8 T\u00a0cells identified in two glioblastoma models using a cancer immunogenomics approach","volume":"4","author":"Johanns","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ccell.2022.12.007_bib71","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T\u00a0cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib72","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","article-title":"Spatiotemporal co-dependency between macrophages and exhausted CD8+ T\u00a0cells in cancer","volume":"40","author":"Kersten","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2022.12.007_bib74","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1172\/JCI123360","article-title":"An osteopontin\/CD44 immune checkpoint controls CD8+ T\u00a0cell activation and tumor immune evasion","volume":"128","author":"Klement","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2022.12.007_bib75","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/sj.bjc.6605834","article-title":"Osteopontin is a marker for cancer aggressiveness and patient survival","volume":"103","author":"Weber","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ccell.2022.12.007_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12253-008-9130-0","article-title":"Correlation between osteopontin protein expression and histological grade of astrocytomas","volume":"15","author":"Toy","year":"2009","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ccell.2022.12.007_bib77","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1158\/1055-9965.EPI-09-1077","article-title":"Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis","volume":"19","author":"Sreekanthreddy","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ccell.2022.12.007_bib78","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/1078-0432.CCR-21-1881","article-title":"T-Cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas","volume":"28","author":"Kilian","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2022.12.007_bib79","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coi.2021.09.005","article-title":"The role of CD4 T\u00a0cells in rejection of solid tumors","volume":"74","author":"Poncette","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ccell.2022.12.007_bib80","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T\u00a0cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib81","doi-asserted-by":"crossref","first-page":"12810","DOI":"10.3390\/ijms222312810","article-title":"Genetically modified cellular therapies for malignant gliomas","volume":"22","author":"Kilian","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ccell.2022.12.007_bib82","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T\u00a0cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2022.12.007_bib83","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T\u00a0cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in\u00a0vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ccell.2022.12.007_bib84","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2022.12.007_bib85","first-page":"e78","article-title":"CLUE: a bioinformatic and wet-lab pipeline for multiplexed cloning of custom sgRNA libraries","volume":"48","author":"Becker","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ccell.2022.12.007_bib86","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610822005931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535610822005931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:05:14Z","timestamp":1778817914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610822005931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1535610822005931"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2022.12.007","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.10.495502","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2022.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}